Novelos Therapeutics Enrolls 1st Patient in Pivotal Phase 3 Lung Cancer Trial
Monday November 6, 8:30 am ET
Full Enrollment Expected in 1Q 2008
NEWTON, Mass.--(BUSINESS WIRE)--Novelos Therapeutics, Inc. (OTCBB: NVLT - News), a biotechnology company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the first patient has been enrolled in the pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) for its lead product NOV-002 in combination with first-line chemotherapy. Thomas Lynch, M.D. and Panos Fidias, M.D. from Massachusetts General Hospital (MGH) are the trial co-Chairs. Dr. Lynch is Director of MGH's Center for Thoracic Cancers and Dr. Fidias is Clinical Director for the Center.
This randomized, open-label, international Phase 3 trial is being conducted under a Special Protocol Assessment (SPA) and will study 840 patients with Stage IIIb/IV NSCLC.
2007-01-22
07:07:51
·
1 answers
·
asked by
Bixbyte
4